• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Reinforced safety profile of Boehringer Ingelheim’s Pradaxa released

Reinforced safety profile of Boehringer Ingelheim’s Pradaxa released

November 19, 2013
CenterWatch Staff

Boehringer Ingelheim Pharmaceuticals has announced results from a new, long-term, combined analysis of the pivotal phase III RE-LY trial and its extension safety study RELY-ABLE. The data showed that after a median follow up of 4.6 years, with some patients followed up to 6.7 years, rates of stroke/systemic embolism and major bleeding were consistent with rates in previously reported analyses of RE-LY, one of the largest stroke prevention clinical studies ever conducted in patients with non-valvular atrial fibrillation (NVAF).

"This is the first set of data to provide results after long-term continuous follow-up of more than four years in a large set of NVAF patients who were treated with one of the newer oral anticoagulants (OAC)," said Michael D. Ezekowitz, M.D., Ph.D., FACC, professor of medicine at Thomas Jefferson Medical College in Philadelphia. "Patients with NVAF need long-term treatment with anticoagulants in order to lower their risk of stroke, and these data are crucial in understanding PRADAXA's long-term safety in patients with NVAF."

Following the RE-LY trial, a total of 5,851 patients, who were randomized to either 110mg or 150mg twice daily (BID) of dabigatran, continued the same blinded dose of dabigatran in RELY-ABLE. Median follow up was 4.6 years, with a maximum 6.7 years total follow up (RE-LY plus RELY-ABLE). This new analysis showed that the rates of stroke or systemic embolism for dabigatran 150mg BID and 110mg BID were 1.25% and 1.54% per year, respectively.

The low rates of hemorrhagic stroke seen during RE-LY (approximately one case per thousand per year) were observed over the whole duration of follow-up. Mortality rates were similar for the two dabigatran doses: 3.43% per year for 150mg BID and 3.55% per year for 110mg BID; HR 0.97 (95% CI: 0.87-1.08). Additional results from the combined analysis of RE-LY and RELY-ABLE included: Rates of ischemic stroke for dabigatran 150mg BID and 110mg BID at 1.03% and 1.29% per year, respectively and rates of major hemorrhage for dabigatran 150mg BID and 110mg BID at 3.34% and 2.76% per year, respectively.

"We are pleased that these long-term results are consistent with our pivotal RE-LY data and support PRADAXA 150mg twice daily as an important treatment option in patients with NVAF when used as directed," said Sabine Luik, M.D., senior vice president, Medicine & Regulatory Affairs, U.S. regional medical director, Boehringer Ingelheim Pharmaceuticals.

PRADAXA was the first OAC approved by the FDA in more than 50 years to reduce the risk of stroke and systemic embolism in patients with NVAF. PRADAXA is the only OAC to be shown to be superior to warfarin in reducing ischemic stroke, a key consideration in anticoagulant therapy given that nearly nine out of 10 strokes caused by atrial fibrillation (AFib) are ischemic strokes. Since its discovery 20 years ago, PRADAXA has been evaluated through the extensive RE-VOLUTION clinical trial program, which includes 10 completed clinical trials involving approximately 40,000 patients in more than 44 countries.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing